Lucid Diagnostics Inc Total Assets
Lucid Diagnostics Inc total assets. Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) holds total assets worth $38.95 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LUCD company net worth for the company's overall valuation and market capitalisation.
Total Assets of Lucid Diagnostics Inc (2018–2025)
Total assets of Lucid Diagnostics Inc from 2018 to 2025. This chart illustrates how Lucid Diagnostics Inc's total assets have evolved over time, based on quarterly financial data. See latest Lucid Diagnostics Inc stock price today for real-time trading data and today's change.
Lucid Diagnostics Inc - Asset Composition Analysis
Lucid Diagnostics Inc Total Assets Breakdown (December 2025)
Lucid Diagnostics Inc total assets breakdown as of December 2025. Lucid Diagnostics Inc's total assets of $38.95 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.8% |
| Accounts Receivable | $643.00K | 1.6% |
| Inventory | $353.00K | 0.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $315.00K | 0.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Lucid Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Lucid Diagnostics Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lucid Diagnostics Inc's current assets represent 92.6% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 85.8% of total assets in 2025, down from 100.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Lucid Diagnostics Inc Competitors by Total Assets
Key competitors of Lucid Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Lucid Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 1.15 | 0.09 |
| Quick Ratio | 1.31 | 1.12 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.11 Million | $4.41 Million | $-24.93 Million |
Lucid Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Lucid Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.69 |
| Latest Market Cap to Assets Ratio | 1.93 |
| Asset Growth Rate (YoY) | 31.7% |
| Total Assets | $40.45 Million |
| Market Capitalization | $78.10 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lucid Diagnostics Inc's assets above their book value (1.93x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Lucid Diagnostics Inc's assets grew by 31.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lucid Diagnostics Inc (2018–2025)
The table below shows the annual total assets of Lucid Diagnostics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $40.45 Million | +31.68% |
| 2024-12-31 | $30.71 Million | +12.63% |
| 2023-12-31 | $27.27 Million | -16.12% |
| 2022-12-31 | $32.51 Million | -44.90% |
| 2021-12-31 | $59.00 Million | +2587.88% |
| 2020-12-31 | $2.19 Million | +112.30% |
| 2019-12-31 | $1.03 Million | +5708.43% |
| 2018-12-31 | $17.80K | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more